Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
Serum C-peptide was measured fasting and 6 minutes after glucagon (1 mg given intravenously) in 49 patients with non-insulin-dependent diabetes mellitus, after 4 and 6 months of successive periods of treatment with insulin and oral hypoglycaemics (glibenclamide and metformin), given in random order. Glycaemic control was not significantly different on the two treatments, but C-peptide was much higher while the patients were on glibenclamide. We conclude that glibenclamide stimulates pancreatic insulin production even after 6 months treatment.
D000328:Adult; D000368:Aged; D002096:C-Peptide / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors
D002096:C-Peptide; D007328:Insulin; D008687:Metformin; D005905:Glyburide